findmyKOL

Eric Kleerup, MD

Basic profile

University of California, Los Angeles

ORCIDNone on fileNPI
RegionLos Angeles, CA · WestSpecialtyPulmonary DiseaseFocusRespiratory
Last active 2021findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2021Online presenceNot yet checkedPaymentsNone reportedNIH funding2011–2016Why? →

Eric Kleerup is a Respiratory physician affiliated with University of California, Los Angeles. OpenAlex indexes 156 publications with 9,875 citations (h-index 47); ClinicalTrials.gov lists 3 registered studies matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
156publications

Distinct works indexed by OpenAlex.

9,875citations

Total citations across indexed works.

47h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
3clinical trials

Investigator role on registered studies.

View trials
1NIH grants · 2011–2016

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

200 Medical Plaza
#365,530,420,120
Los Angeles, CA 90095

Telephone

310-825-6301

Registry record last updated 28 Jun 2010.

View the NPPES registry record

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Respiratory

    72.3%
    Corticosteroid39.9%
    Fluticasone Propionate23%Trelegy Ellipta17%Dulera14%Breo Ellipta13%Symbicort8%Qvar Redihaler7%Asmanex Hfa5%Breyna4%Fluticasone Propionate Hfa4%Arnuity Ellipta3%Breztri Aerosphere3%
    Part D<11 patients
    beta2-Adrenergic Agonist19.5%
    Albuterol Sulfate Hfa78%Ventolin Hfa18%Serevent Diskus5%
    Part D<11 patients

    + 4 more classes in this area

  • Metabolism & gastrointestinal

    16.2%
    Proton pump inhibitor8.6%
    Omeprazole56%Esomeprazole Magnesium44%
    Part D23 patients
    Corticosteroid5.2%
    Prednisone100%
    Part D33 patients

    + 1 more class in this area

  • Anti-infectives

    6.2%
    Macrolide Antimicrobial3.5%
    Azithromycin100%
    Part D20 patients
    Fluoroquinolone Antibacterial1.6%
    Levofloxacin100%
    Part D15 patients

    + 1 more class in this area

Where care is delivered (Part B)91.3% facility · 8.7% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 20112016 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”